Do Antidepressants Cause Tardive Dyskinesia?
Antidepressants alone do not cause tardive dyskinesia in adults without prior or concurrent exposure to dopamine receptor-blocking agents (DRBDs), though they may unmask or exacerbate TD after prior DRBD exposure. 1
Evidence for Antidepressants and TD
Primary Mechanism and Causation
Tardive dyskinesia is fundamentally a disorder caused by chronic exposure to dopamine receptor-blocking drugs, primarily antipsychotics and antiemetics. 2, 3
A comprehensive literature review found that evidence supporting antidepressants causing TD-like syndrome by themselves is "extremely weak," with most reported cases occurring as a result of a "priming" effect induced by prior DRBD exposure. 1
Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may unmask or exacerbate TD after prior exposure to or with concurrent use of DRBDs, but support for TD occurring outside this context is minimal. 1
Specific Antidepressant Considerations
Bupropion:
- The FDA label for bupropion lists "unmasking tardive dyskinesia" and "dyskinesia" as nervous system adverse reactions, indicating it can reveal pre-existing TD rather than cause it de novo. 4
Duloxetine:
- One case report documented tardive dystonia and tardive dyskinesia in a 58-year-old woman after 18 months of duloxetine (30-60 mg daily), with only partial remission after discontinuation. 5
- However, this represents an extremely rare occurrence, and the mechanism remains unclear given duloxetine's lack of significant dopamine receptor blockade. 5
Tricyclic Antidepressants:
- Historical case reports from 1976 documented dyskinetic syndromes with TCAs, hypothesized to relate to anticholinergic activity rather than dopamine blockade. 6
- TCAs are known to have little effect on striatal dopamine but share potent anticholinergic activity with neuroleptics. 6
Clinical Implications and Risk Assessment
When Evaluating Movement Disorders in Patients on Antidepressants
Always obtain a complete medication history, including any antipsychotics or antiemetics used in the past, as TD can persist even after the offending agent is discontinued. 2
Investigate prior emergency department visits where antipsychotics may have been administered, as patients may not recall or report these exposures. 2
Document baseline abnormal movements before initiating any psychotropic medication to avoid mislabeling pre-existing conditions. 2, 7
Common Pitfall to Avoid
Do not assume antidepressants are the primary cause when TD appears in a patient taking only antidepressants—thoroughly investigate for prior DRBD exposure, as the antidepressant is likely unmasking pre-existing subclinical TD rather than causing it. 1
The European Society of Cardiology guidelines note that tricyclic antidepressants are associated with QTc prolongation and arrhythmic risk, but this is distinct from TD causation. 8
Management if TD Develops
If TD is suspected in a patient on antidepressants with no clear DRBD history, discontinue the antidepressant and monitor for resolution. 2
For moderate to severe TD, treat with VMAT2 inhibitors (valbenazine or deutetrabenazine) as first-line pharmacotherapy regardless of the suspected causative agent. 2, 7, 9
Monitor using the Abnormal Involuntary Movement Scale (AIMS) every 3-6 months. 2, 7